MX2022011800A - Metodos para tratar mieloma multiple. - Google Patents
Metodos para tratar mieloma multiple.Info
- Publication number
- MX2022011800A MX2022011800A MX2022011800A MX2022011800A MX2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- multiple myeloma
- treating multiple
- antibody
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Luminescent Compositions (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000229P | 2020-03-26 | 2020-03-26 | |
| PCT/US2021/024127 WO2021195362A1 (en) | 2020-03-26 | 2021-03-25 | Methods of treating multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011800A true MX2022011800A (es) | 2023-01-19 |
Family
ID=75540019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011800A MX2022011800A (es) | 2020-03-26 | 2021-03-25 | Metodos para tratar mieloma multiple. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230118517A1 (https=) |
| EP (1) | EP4126952A1 (https=) |
| JP (1) | JP2023520771A (https=) |
| KR (1) | KR20230005163A (https=) |
| CN (1) | CN115698069A (https=) |
| AU (1) | AU2021244215A1 (https=) |
| BR (1) | BR112022018987A2 (https=) |
| CA (1) | CA3176257A1 (https=) |
| IL (1) | IL296723A (https=) |
| MX (1) | MX2022011800A (https=) |
| TW (1) | TW202202170A (https=) |
| WO (1) | WO2021195362A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170233484A1 (en) | 2016-02-17 | 2017-08-17 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| PE20241326A1 (es) * | 2021-11-05 | 2024-06-26 | Springworks Therapeutics Inc | Composiciones y tratamientos con nirogacestat |
| EP4473132A4 (en) * | 2022-02-03 | 2025-12-17 | Predicine Inc | SYSTEMS AND METHODS FOR MONITORING CANCER WITH MINIMUM RESIDUAL DISEASE ANALYSIS |
| IL316750A (en) * | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US662510A (en) | 1899-05-20 | 1900-11-27 | Western Electric Co | Incandescent-lamp socket. |
| CH646696A5 (de) | 1980-11-28 | 1984-12-14 | Sandoz Ag | Dibenzazepine, ihre herstellung und verwendung. |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| WO2000046750A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| CA2397543A1 (en) | 2000-01-24 | 2001-07-26 | Timothy Harrison | Gamma-secretase inhibitors |
| GB0005251D0 (en) | 2000-03-03 | 2000-04-26 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| AU2002210747B2 (en) | 2000-11-02 | 2006-06-01 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| UA77165C2 (en) | 2000-11-17 | 2006-11-15 | Lilly Co Eli | (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| GB0223038D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0225474D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| GB0326039D0 (en) | 2003-11-07 | 2003-12-10 | Merck Sharp & Dohme | Therapeutic agents |
| BRPI0513959A (pt) | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| US8377886B2 (en) | 2007-09-14 | 2013-02-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
| US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10149855B2 (en) | 2014-02-05 | 2018-12-11 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides |
| CA2952315A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
| PL3988117T3 (pl) * | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| US20170233484A1 (en) * | 2016-02-17 | 2017-08-17 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| US10307388B2 (en) | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019094626A1 (en) | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| SG11202011589WA (en) | 2018-05-24 | 2020-12-30 | Ayala Pharmaceuticals Inc | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| US11773369B2 (en) | 2018-08-03 | 2023-10-03 | The Regents Of The University Of California | Generation of human spinal cord neural stem cells |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| WO2020212914A1 (en) | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses |
| KR20250030524A (ko) | 2019-08-09 | 2025-03-05 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도 |
-
2021
- 2021-03-25 BR BR112022018987A patent/BR112022018987A2/pt unknown
- 2021-03-25 JP JP2022558137A patent/JP2023520771A/ja active Pending
- 2021-03-25 IL IL296723A patent/IL296723A/en unknown
- 2021-03-25 AU AU2021244215A patent/AU2021244215A1/en not_active Abandoned
- 2021-03-25 US US17/913,542 patent/US20230118517A1/en active Pending
- 2021-03-25 MX MX2022011800A patent/MX2022011800A/es unknown
- 2021-03-25 EP EP21719439.8A patent/EP4126952A1/en not_active Withdrawn
- 2021-03-25 WO PCT/US2021/024127 patent/WO2021195362A1/en not_active Ceased
- 2021-03-25 CN CN202180038796.8A patent/CN115698069A/zh active Pending
- 2021-03-25 CA CA3176257A patent/CA3176257A1/en active Pending
- 2021-03-25 KR KR1020227036505A patent/KR20230005163A/ko not_active Abandoned
- 2021-03-26 TW TW110111220A patent/TW202202170A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL296723A (en) | 2022-11-01 |
| EP4126952A1 (en) | 2023-02-08 |
| CN115698069A (zh) | 2023-02-03 |
| AU2021244215A1 (en) | 2022-10-13 |
| US20230118517A1 (en) | 2023-04-20 |
| TW202202170A (zh) | 2022-01-16 |
| WO2021195362A1 (en) | 2021-09-30 |
| BR112022018987A2 (pt) | 2022-11-01 |
| KR20230005163A (ko) | 2023-01-09 |
| JP2023520771A (ja) | 2023-05-19 |
| CA3176257A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011800A (es) | Metodos para tratar mieloma multiple. | |
| MX2021012407A (es) | Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa. | |
| CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| EA202191176A1 (ru) | Поливалентные модуляторы регуляторных т-клеток | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| PH12021551451A1 (en) | Combination hbv therapy | |
| CY1126559T1 (el) | Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης | |
| BR112022001336A8 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
| EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
| ZA202200905B (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
| PH12021551494A1 (en) | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| JOP20220007A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| JOP20220168A1 (ar) | طرق علاج الطحال | |
| ZA202309150B (en) | Antibody against nkp46 and application of antibody | |
| MX2018002554A (es) | Combinaciones de inhibidores de btk para tratar mieloma multiple. | |
| MX2024001888A (es) | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. | |
| EP4252847A3 (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| JOP20210279A1 (ar) | طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي | |
| ECSP21091482A (es) | Terapia de combinación | |
| CO2021014370A2 (es) | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen | |
| CO2022009433A2 (es) | Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario | |
| MX2023002852A (es) | Terapia de combinacion para el cancer. |